8-K: Phio Pharma Raises $13.4M via Warrant Exercises

Phio Pharmaceuticals Corp. secured approximately $13.4 million in gross proceeds through inducement letter agreements for the exercise of existing warrants and the issuance of new Series A warrants.

Summary

• Phio Pharmaceuticals Corp. entered into inducement letter agreements on November 3, 2025, with certain holders to exercise existing common stock warrants.
• A total of 5,663,182 shares from existing warrants were exercised.
• Exercise prices for these existing warrants ranged from $2.00 to $5.45 per share, with a significant portion (4,654,586 shares) exercised at a reduced price of $2.05 per share.
• In consideration, the company issued new unregistered Series A Warrants to purchase up to 11,326,364 shares of common stock (200% of the exercised existing warrants).
• The new Series A Warrants have an exercise price of $2.05 per share, are immediately exercisable, and have a 24-month term from the effective date of their resale registration statement.
• The gross proceeds from the exercise of existing warrants and the issuance of new warrants are expected to be approximately $13.4 million.
• H.C. Wainwright & Co. acted as the exclusive placement agent, receiving a 7.5% cash fee, a 1.0% management fee, and additional expenses totaling $100,950.
• The placement agent also received warrants to purchase up to 424,739 shares of common stock, with various exercise prices and a 24-month term.
• The company intends to use the net proceeds for working capital and to accelerate development activities for its lead clinical program, PH-762, for cutaneous carcinomas.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding for a clinical-stage biotech, which is positive for continued operations and advancing its lead program. However, the terms, including reduced exercise prices for existing warrants and significant potential dilution from new warrants and placement agent warrants, indicate a cost to securing this capital. The high placement agent fees also detract from the net proceeds. The positive clinical update for PH-762 partially offsets these dilutive aspects.

Positives

• Secured approximately $13.4 million in gross proceeds, providing capital for operations and clinical development.
• Funds will primarily be used to accelerate required development activities for PH-762, preparing for the next phase of clinical development, following recent positive safety and pathology outcomes in its dose escalating trial.
• The transaction demonstrates continued investor interest and support, albeit with inducement terms.

Negatives

• A significant portion of existing warrants (4,654,586 shares) were exercised at a reduced price of $2.05 per share, potentially below their original exercise prices of up to $5.45, indicating a concession to warrant holders.
• The issuance of new unregistered Series A Warrants (up to 11,326,364 shares) and Placement Agent Warrants (up to 424,739 shares) represents potential future dilution for existing shareholders.
• Substantial fees and expenses are payable to the placement agent, including 7.5% cash fee, 1.0% management fee, and $100,950 in other expenses, reducing net proceeds.
• The company agreed to a 15-calendar day lock-up period after closing, restricting further equity issuances or registration statement filings (with exceptions), which could limit immediate financing flexibility.

Risks

• The new Series A Warrants and Placement Agent Warrants are unregistered and may not be offered or sold without registration or an applicable exemption, potentially limiting liquidity for holders.
• The company is obligated to file a resale registration statement for the new warrant shares within 20 calendar days and use best efforts to make it effective within 50-80 calendar days, with penalties for delays.
• Failure to timely deliver warrant shares upon exercise or to maintain an effective registration statement could result in liquidated damages and other remedies for holders.
• The beneficial ownership limitation (4.99% or 9.99%) may restrict the immediate exercise of all warrants by certain holders, leading to shares being held in abeyance.
• The forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances, including inflationary pressures, rising interest rates, recession fears, and the success of product candidate development and regulatory approvals.

Future Outlook

The company intends to use the net proceeds from this offering for general working capital and, more specifically, to accelerate the completion of required development activities for its lead clinical program, PH-762, in preparation for its next phase of clinical development for cutaneous carcinomas. This acceleration is driven by recent positive safety and pathology outcomes observed in the ongoing dose-escalating trial.

Management Comments

• "Phio intends to use the net proceeds from these warrant exercises for working capital, and, primarily, accelerated completion of certain required development activities in preparation for the next phase of clinical development of PH-762 for cutaneous carcinomas given recent positive safety and pathology outcomes in its dose escalating trial."

Industry Context

As a clinical-stage biopharmaceutical company, Phio Pharmaceuticals relies heavily on capital raises to fund its research and development activities. This financing event provides crucial capital to advance its lead immuno-oncology therapeutic, PH-762, which targets skin cancers. The focus on accelerating clinical development for PH-762, particularly after positive early trial outcomes, aligns with typical strategies in the biotech sector to de-risk assets and move towards later-stage trials and potential commercialization. The structure of the deal, involving inducement to exercise existing warrants and issuing new ones, is a common mechanism for companies to raise capital, especially when share prices may be below previous warrant exercise prices.

Comparison to Industry Standards

• The issuance of new warrants as an inducement for existing warrant exercises, particularly with a 200% coverage ratio (two new warrants for each exercised share), is a relatively aggressive financing strategy often seen in smaller, clinical-stage biotech companies seeking to shore up capital quickly. This can be more dilutive than traditional equity offerings.
• Placement agent fees totaling 8.5% (7.5% cash + 1.0% management fee) plus additional warrants (7.5% of exercised shares) and fixed expenses are on the higher end of industry norms for 'reasonable best-efforts' private placements, reflecting the perceived risk or urgency of the capital raise for a clinical-stage company.
• The use of proceeds for accelerating clinical development, especially after positive early-stage data, is a standard and expected capital allocation strategy for biopharmaceutical companies aiming to progress their pipeline and increase asset value.

Stakeholder Impact

• **Shareholders:** Existing shareholders face potential dilution from the issuance of new Series A Warrants (up to 11,326,364 shares) and Placement Agent Warrants (up to 424,739 shares). The reduced exercise price for a large portion of existing warrants also implies a lower valuation for those shares compared to their original terms. However, the capital infusion provides runway for continued operations and clinical development, which could ultimately benefit shareholders if PH-762 progresses successfully.
• **Warrant Holders:** Holders of existing warrants were incentivized to exercise their warrants, some at a reduced price, and received new Series A Warrants, providing them with additional upside potential and liquidity options once the resale registration statement is effective.
• **Employees:** The capital raise helps ensure the company's financial stability, supporting ongoing employment and the continuation of research and development efforts.
• **Creditors:** The additional capital strengthens the company's balance sheet, potentially improving its creditworthiness.
• **H.C. Wainwright & Co. (Placement Agent):** Received substantial fees and warrants as compensation for facilitating the offering.

Next Steps

• Additional closings of the offering are expected to occur by November 18, 2025.
• The company will file a registration statement for the resale of the New Warrant Shares within 20 calendar days from November 3, 2025.
• The company will use best efforts to cause the resale registration statement to become effective within 50 calendar days (or 80 days if full SEC review) from November 3, 2025.
• The company plans to accelerate required development activities for PH-762 in preparation for its next phase of clinical development for cutaneous carcinomas.

Key Dates

Recommendation

While the capital raise provides essential funding for Phio Pharmaceuticals to advance its clinical programs, the terms of the financing are significantly dilutive. The inducement to exercise existing warrants at reduced prices, coupled with the issuance of new warrants at a 200% coverage ratio and substantial placement agent fees, suggests a high cost of capital. The positive clinical update for PH-762 is a favorable development, but the immediate and potential future dilution warrants a cautious 'hold' recommendation. Investors should monitor the progress of PH-762's clinical development and the company's ability to manage future dilution effectively before considering a stronger position.

Keywords

Phio Pharmaceuticals, PHIO, Warrant Exercise, Capital Raise, Equity Financing, Biopharmaceutical, siRNA, Immuno-oncology, PH-762, Cutaneous Carcinoma, SEC Filing, Form 8-K, Warrants, Private Placement